ILIU Stock UPDATES Interleukin Genetics (ILIU) 0.2700 08/30/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Interleukin Genetics (ILIU) 0.2700 $ILIU

Interleukin Genetics Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 13, 3:20PM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today issued financial and operational results for its fiscal second quarter ended June 30, 2014.

Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2014 Results
Business Wire - Wed Aug 06, 3:15PM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and Webcast on Wednesday, August 13, 2014 at 4:30 p.m. (ET) to provide a corporate update and discuss the Company's second quarter results. The Company will also provide a slide presentation.

Interleukin Genetics Announces Changes to Its Board of Directors
Business Wire - Mon Mar 31, 3:05PM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced several changes to the Company's Board of Directors. Joseph Landstra, Director of Finance at Alticor Corporate Enterprises, will join the Board as a Director, filling the seat previously vacated by James Weaver as a representative of Pyxis Innovations Inc., who is leaving Pyxis' parent company, Alticor to pursue other interests. Mr. Landstra, a certified public accountant with a background in corporate audit and finance, will also serve on the Audit Committee of the Board. He joins Roger C. Colman, Director, in representing the interests of Pyxis as Interleukin's partner and shareholder. In addition, Mr. Weaver will rejoin the Company as an independent director and will resume his role as Chairman. Lastly, Goran Jurkovic has stepped down from his current role as a member of the Board of Directors due to the requirements of other professional commitments. Mr. Jurkovic currently serves as Senior Vice President and Chief Financial Officer of Delta Dental of Michigan and affiliated companies.

Interleukin Genetics Reports Fourth Quarter and Year-End 2013 Financial Results
Business Wire - Thu Mar 20, 3:20PM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today issued financial and operational results for its fiscal fourth quarter and full fiscal year ended December 31, 2013.

Interleukin Genetics, Inc. Announces Conference Call to Discuss Fourth Quarter 2013 Results
Business Wire - Thu Mar 13, 5:02PM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and Webcast on Thursday, March 20, 2014 at 4:30 p.m. (ET) to provide a corporate update and discuss the Company's fourth quarter and 2013 year end results.

PhotoMedex Appoints Trevor S. Harris to Its Board of Directors
Business Wire - Tue Mar 04, 7:30AM CST
PhotoMedex, Inc. (NasdaqGS and TASE: PHMD) announces the appointment of Trevor S. Harris, Ph.D., CA (SA) to the Company's board of directors, returning the board's size to eight members. Effective April 1, 2014, Dr. Harris will also serve as chairman of the Company's audit committee. He replaces Dr. Nahum Melumad, who passed away on January 15, 2014.

Global Personalized Medicine Diagnostics Market 2012-2016: AltheaDx Inc. Launches FLT3 Mutation Assay in October 2012
M2 - Tue Aug 06, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x63hs3/global) has announced the addition of the "Global Personalized Medicine Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Personalized Medicine Diagnostics market to grow at a CAGR of 4.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicine for treating cancer. The Global Personalized Medicine Diagnostics market has also been witnessing an increase in the number of industrial activities. However, the low awareness of personalized medicine diagnostics in developing countries could pose a challenge to the growth of this market. The key vendors dominating this space include Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMerieux SA, Illumina Inc., and Roche Holding AG. Commenting on the report, an analyst from the team said: One of the main trends witnessed in the Global Personalized Medicine Diagnostics market is the development of innovative tools and technologies. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Furthermore, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 to predict the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. According to the report, one of the main factors driving the market is the increasing demand for personalized medicine diagnostics for treatment of cancer. Hyperthermia is one of the treatments of cancer where the use of personalized medicines and diagnostics is considered depending on a patient's specific attributes. Methods of treatments such as hyperthermia and radiotherapy have already been proposed. Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries. Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Becton Dickinson and Company - bioMerieux SA - Illumina Inc. - Roche Holding AG. - 20/20 GeneSystems Inc. - Accumetrics Inc. - AdvanDx Inc. - Affymetrix Inc. - Almac Group Ltd. - AltheaDx Inc. - Ambry Genetics Corp. - Amgen Inc. - Arrayit Corp. - AssureRx Health Inc. - Autogenomics Inc. - BG Medicine Inc. - Biocare Medical LLC - Biocartis SA - Biocept Inc. - BioCurex Inc. - Biodesix Inc. - Bio-Reference Laboratories Inc. - CombiMatrix Corp. - Corgenix Medical Corp. - DxTerity Diagnostics Inc. - EnzoBiochem Inc. - Epigenomics AG - Euroimmun AG - GE Healthcare - Genomic Health Inc. - Interleukin Genetics Inc. - Johnson & Johnson - Knome Inc. - Lab21 Ltd. - Life Technologies Corp. - MDxHealth SA - Myriad Genetics Inc. - Nanosphere Inc. - Pathway Genomics Corp. - Power3 Medical Products Inc. - Quest Diagnostics Inc. - Response Genetics Inc. - Rosetta Genomics Ltd. - Sequenom Inc. - Trovagene Inc. - Vermillion Inc. - Viracor-IBT Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/x63hs3/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Study Published in Journal of Dental Research Demonstrates Value of Genetics in Preventing Periodontal Disease
Business Wire - Mon Jun 10, 10:32AM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) today announced the online publication of the research study "Patient Stratification for Preventive Dental Care" in Journal of Dental Research. The study provides new insights into the prevention of periodontitis (gum disease) and the opportunity for significant advancement in the delivery of personalized, preventive dental care. Periodontitis affects 47 percent of the adult population.

Interleukin Genetics to Discuss Corporate Update and First Quarter Results
Business Wire - Thu May 23, 3:05PM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) will host a conference call and Webcast today at 4:30 p.m. (EDT) to provide a corporate update and discuss the Company's first quarter results.

Interleukin Genetics, Inc. Announces Conference Call to Discuss First Quarter 2013 Results
Business Wire - Mon May 20, 11:00AM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and Webcast on Thursday, May 23, 2013 at 4:30 p.m. (EST) to provide a corporate update and discuss the Company's first quarter results.

Interleukin Genetics Announces $12 Million Private Placement
Business Wire - Mon May 20, 6:55AM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it has raised $12.0 million in gross proceeds through a private placement of its securities to accredited investors. Interleukin sold an aggregate of 43,715,847 shares of its common stock at a price of $0.2745 per share and issued warrants to purchase an aggregate of 32,786,885 shares of common stock at an exercise price of $0.2745 per share to the investors.

PST Manuscript Submitted, Awaiting Publication Acceptance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 17, 7:04PM CDT
PST Manuscript Submitted, Awaiting Publication Acceptance

Interleukin Genetics and University of North Carolina Publish Genetic Factors Predictive of Progression of Knee Osteoarthritis
Business Wire - Wed May 08, 7:35AM CDT
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today the online publication in Osteoarthritis and Cartilage of a study with investigators at the Thurston Arthritis Research Center of the University of North Carolina entitled, "IL-1 receptor antagonist gene as a predictive biomarker of progression of knee osteoarthritis in a population cohort."

Initial Agreement With Renaissance Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 04, 4:11PM CST
Interleukin Genetics (OTC Markets:ILIU) penned an initial agreement with Renaissance Health Service Corp (RHSC) relative to reimbursement of the company's PST test.

Interleukin Genetics Appoints Scott Snyder as Chief Marketing Officer
Business Wire - Thu Jan 03, 3:10PM CST
Interleukin Genetics, Inc. (OTCQB: ILIU) today announced the appointment of Scott Snyder as Chief Marketing Officer. In this role, Scott will spearhead the launch of the company's proprietary PST(R) genetic risk panel to guide more effective dental preventive care. Scott will have responsibility for marketing Interleukin's professional healthcare tests, including PST(R) and a proprietary test for osteoarthritis progression, and for the Inherent Health(R) brand of health and wellness genetic tests within consumer channels.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 165

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 0

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 26

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 41

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 467

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 119

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 48

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 51

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 244

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 210

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading

Top 5 Most Recently Viewed Articles

EDF Renewables Partners with OPPD for Sustainable Energy Growth

Updated Category News Views 184

EDF Renewables and Omaha Public Power District Join Forces EDF Renewables North America has announced a significant partnership with Omaha Public Power District (OPPD) to enhance the future of renewable energy. Their collaboration centers around the Milligan 1 Wind project, contributing to a larger initiative aimed at delivering cleaner, reliable energy to communities...

Continue Reading
Seaport Therapeutics Welcomes Lauren White as CFO in Growth Strategy

Updated Category News Views 128

Seaport Therapeutics Appoints Lauren White as Chief Financial Officer Seaport Therapeutics, a pioneering clinical-stage biopharmaceutical firm focused on developing innovative neuropsychiatric therapies, recently announced an important leadership change, naming Lauren White as their new Chief Financial Officer. With an impressive track record in biotech financial...

Continue Reading
Lyte Fiber Secures $58 Million to Enhance Broadband Access

Updated Category News Views 461

Lyte Fiber Secures Funding to Expand Broadband Connectivity Lyte Fiber, LLC, based in Houston, has been awarded nearly $58 million through the State’s Bringing Online Opportunities to Texas (BOOT) II Program. This significant funding initiative aims to connect more than 6,750 underserved homes and businesses, thereby supporting the goal of widening broadband access in...

Continue Reading
Chipotle Faces Challenges as Young Consumers Turn to Home Cooking

Updated Category News Views 233

Understanding Current Dining Trends and Chipotle's Position As inflation continues to affect the retail and restaurant sectors, many dining establishments are feeling the pinch, particularly as lower-income consumers scale back on discretionary spending. Chipotle Mexican Grill Inc. (NYSE: CMG) recently faced significant losses in its stock value, dropping 19% in a single...

Continue Reading
Leadership Changes Propel zerohash for Future Growth

Updated Category News Views 288

Leadership Appointments at Zerohash New York-based zerohash has made significant strides in the crypto and stablecoin sector by welcoming Aaron Karczmer and Danny Rosenthal to its Boards of Directors. Their wealth of experience in payments and regulatory frameworks will be instrumental as the company navigates its next growth phase. Bringing Expertise to the Board Aaron...

Continue Reading